Azenta posts $158M FY2026 continuing-operations loss
Fiscal 2027 outlook anticipates 3%–5% organic growth, with adjusted EBITDA margin expansion guidance inclusive of 100 basis points of expected investment-related dilution.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Azenta, Inc. (AZTA) reported fiscal 2026 continuing-operations revenue of $622 million, up 5% year over year, while organic revenue grew 2%. Fourth-quarter revenue was $167 million, also up 5%, with 2% organic growth. Fiscal-year continuing-operations net loss was $157.9 million, including a $149.1 million noncash goodwill impairment; adjusted EBITDA was $58.3 million, down 12%.
For fiscal 2027, Azenta expects reported revenue of $648 million to $660 million, 3% to 5% organic growth, adjusted EBITDA margin expansion of 200 to 250 basis points, and free cash flow improvement of approximately 25%. The company entered Elegen agreements with fixed license payments totaling $23.0 million and expected aggregate capital deployment of approximately $32.0 million to $71.0 million. It also acquired SynPlexity for a $15.0 million base cash price, plus up to $10.0 million contingent consideration tied to a revenue milestone through September 30, 2029.
Azenta repurchased 4.4 million shares for $118.2 million during fiscal 2026. It completed the sale of B Medical Systems on July 1, 2026, and received repayment of a $35 million vendor loan plus accrued interest on September 3, 2026.
1 point · 0 major1 major · 2 points
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointContinuing-operations revenue increased 5% to $622 million in fiscal 2026.
Negative
- Major pointGoodwill impairment was $149.1 million, alongside a $157.9 million continuing-operations net loss. 8.4% of market cap
- Moderate pointAdjusted EBITDA fell 12% to $58.3 million in fiscal 2026.
Filing Explained
Azenta’s
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Continuing-operations revenue: $622 million
Fourth-quarter continuing-operations revenue: $167 million
Continuing-operations net loss: -$157.9 million
+5 more
8 metrics
Continuing-operations revenue
$622 million
Fiscal 2026; up 5% year over year
Fourth-quarter continuing-operations revenue
$167 million
Quarter ended September 30, 2026; up 5% year over year
Continuing-operations net loss
-$157.9 million
Fiscal 2026
Adjusted EBITDA
$58.3 million
Fiscal 2026; down 12% year over year
Cash, cash equivalents, restricted cash and marketable securities
$506 million
As of September 30, 2026
Fiscal 2027 reported revenue guidance
$648 million to $660 million
Fiscal year ending September 30, 2027
Expected aggregate capital deployment under Elegen agreements
Approximately $32.0 million to $71.0 million
Depending on future equipment purchases and whether Azenta exercises the license conversion option
SynPlexity base purchase price
$15.0 million in cash
Acquisition on October 28, 2026
Key Terms
Organic revenue, Adjusted EBITDA, Free cash flow, Goodwill impairment, +1 more
5 terms
Organic revenue financial
"Organic revenue growth is expected to range approximately between 3%-4%"
Organic revenue is the sales a company generates from its regular business activities after stripping out extra effects like revenue added or lost from buying or selling other businesses and from currency swings. Think of it as measuring how much a store’s own customers increased spending, not growth from opening new stores or temporary price moves; investors use it to judge the true strength and sustainability of a company’s core demand.
Adjusted EBITDA financial
"Adjusted EBITDA was $58.3 million"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Free cash flow financial
"Free cash flow (cash flow from operations less capital expenditures)"
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
Goodwill impairment financial
"a non-cash goodwill impairment charge of $149 million"
Goodwill impairment occurs when a company’s valued reputation or brand strength, known as goodwill, is found to be worth less than previously recorded on its financial statements. This usually happens when the company's performance declines or market conditions change, signaling that the expected benefits from acquisitions or brand value are no longer as strong. It matters to investors because it can indicate that a company's assets are less valuable than initially thought, potentially affecting its overall financial health.
Contingent consideration financial
"provides for contingent consideration of up to $10.0 million"
Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.
Earnings Snapshot
Continuing-operations revenue: $622 million · Guidance included
Fiscal 2026 and fourth quarter ended September 30, 2026
Continuing-operations revenue
$622 million
Up 5% year over year
Organic revenue growth
2%
Up 2% year over year
Continuing-operations net loss
-$157.9 million
Compared with $24.5 million income in fiscal 2025
Adjusted EBITDA
$58.3 million
Down 12% year over year
Diluted EPS from continuing operations
-$3.50 per share
Compared with $0.53 per share in fiscal 2025
Guidance
Fiscal 2027 reported revenue of approximately $648 million to $660 million; organic revenue growth of 3% to 5%; adjusted EBITDA margin expansion of 200 to 250 basis points; free cash flow improvement of approximately 25% relative to fiscal 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did AZTA report for fiscal 2026?
Azenta reported $622 million in continuing-operations revenue for fiscal 2026, up 5% year over year, with organic revenue growth of 2%. Fourth-quarter continuing-operations revenue was $167 million, also up 5% year over year.
What is AZTA's fiscal 2027 guidance?
Azenta expects fiscal 2027 reported revenue of $648 million to $660 million, organic revenue growth of 3% to 5%, adjusted EBITDA margin expansion of 200 to 250 basis points, and free cash flow improvement of approximately 25% relative to fiscal 2026.
What are the terms of AZTA's Elegen agreements?
The agreements include an exclusive, royalty-free license to certain Elegen technologies, subject to specified restrictions, with an initial five-year term and fixed license payments totaling $23.0 million. Azenta may convert it to a perpetual license between 12 and 18 months after execution for $25.0 million plus unpaid license fees. Expected aggregate capital deployment is approximately $32.0 million to $71.0 million.
How much did AZTA pay for SynPlexity?
Azenta acquired SynPlexity for a $15.0 million base purchase price in cash, of which approximately $2.5 million was held back subject to customary closing and post-closing adjustments. The purchase agreement also provides for contingent consideration of up to $10.0 million based on a specified revenue milestone through September 30, 2029.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 10, 2026
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices and Zip Code)
(888 ) 229-3682
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition
On November 10, 2026, Azenta, Inc. (“Azenta”) issued a press release announcing financial results for the fiscal quarter and year ended September 30, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. This Current Report on Form 8-K and the press release attached hereto are being furnished by Azenta pursuant to Item 2.02 of Form 8-K. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
| EXHIBIT NUMBER | DESCRIPTION | |||||||
| 99.1 | Earnings press release issued on November 10, 2026 by Azenta, Inc | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AZENTA, INC. | |||||
| /s/ Ephraim Starr | |||||
| Date: November 10, 2026 | Ephraim Starr | ||||
| Senior Vice President, General Counsel and Secretary | |||||
Exhibit 99.1
Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.
•Q4'26 reported revenue growth of 5% year over year and 2% on an organic basis
•FY'26 reported revenue growth of 5% year over year and 2% on an organic basis
•FY'27 reported revenue expected to range from $648 to $660 million
•FY'27 organic revenue growth expected to range between 3% to 5% year over year
•FY'27 adjusted EBITDA margin expected to expand approximately 200 to 250 basis points year over year
BURLINGTON, Mass., November 10, 2026 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2026.
B Medical Systems is reported as discontinued operations, with its historical results reflected in total diluted EPS. The Company completed the sale of the business on July 1, 2026, and received full repayment of the $35 million vendor loan, together with accrued interest, on September 3, 2026.
| Quarter Ended | Year Ended | |||||||||||||||||||||||||||||||||||||
| Dollars in millions, except per share data | September 30, | September 30, | September 30, | September 30, | ||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | |||||||||||||||||||||||||||||||||
| Revenue from Continuing Operations | $ | 167 | $ | 159 | 5 | % | $ | 622 | $ | 594 | 5 | % | ||||||||||||||||||||||||||
| Organic growth | 2 | % | 2 | % | ||||||||||||||||||||||||||||||||||
| Sample Management Solutions | $ | 94 | $ | 86 | 9 | % | $ | 344 | $ | 325 | 6 | % | ||||||||||||||||||||||||||
| Multiomics | $ | 73 | $ | 73 | 0 | % | $ | 277 | $ | 269 | 3 | % | ||||||||||||||||||||||||||
| Diluted EPS Continuing Operations | $ | 0.14 | $ | 1.12 | (88) | % | $ | (3.50) | $ | 0.53 | NM | |||||||||||||||||||||||||||
| Diluted EPS Total | $ | 0.16 | $ | 1.11 | (86) | % | $ | (3.70) | $ | (1.22) | NM | |||||||||||||||||||||||||||
| Net Income (Loss) - Continuing Operations | $ | 6 | $ | 52 | (89) | % | $ | (158) | $ | 24 | NM | |||||||||||||||||||||||||||
| Adjusted Diluted EPS Continuing Operations | $ | 0.28 | $ | 0.21 | 33 | % | $ | 0.48 | $ | 0.51 | (6) | % | ||||||||||||||||||||||||||
| Adjusted EBITDA - Continuing Operations | $ | 19 | $ | 21 | (7) | % | $ | 58 | $ | 66 | (12) | % | ||||||||||||||||||||||||||
| Adjusted EBITDA Margin - Continuing Operations | 11.6 | % | 13.0 | % | 9.4 | % | 11.2 | % | ||||||||||||||||||||||||||||||
1
Management Comments
“We closed fiscal 2026 with improving momentum, delivering stronger performance in the second half of the year. Our businesses have strong market positions and differentiated capabilities, and we are seeing progress from our efforts to improve commercial execution and operating efficiency,” said Dr. Martin Madaus, Interim President and Chief Executive Officer. “We also took several actions to streamline our cost structure while advancing the strategic objective to turn Multiomics into a growth engine for Azenta."
Dr. Madaus continued, “Fiscal 2027 is about consistent execution and accelerating performance. We are focused on driving organic growth, expanding profitability and cash generation, and executing on our strategic initiatives."
Fourth Quarter Fiscal 2026 Results - Continuing Operations
•Revenue was $167 million, up 5% year over year. Organic revenue, which excludes a nominal impact from foreign exchange and a 3-percentage point impact from the acquisition of UK Biocentre Limited, was up 2% year over year, reflecting organic growth in Sample Management Solutions, partially offset by an organic revenue decline in Multiomics.
•Sample Management Solutions revenue was $94 million, up 9% year over year.
◦Organic revenue, which excludes the impact from foreign exchange and the contribution from the acquisition of UK Biocentre Limited, was up 4%, mainly driven by higher revenue in Sample Repository Services and Consumables and Instruments, partially offset by lower revenue in Automated Stores.
•Multiomics revenue was $73 million, flat year over year.
◦Organic revenue, which excludes the impact from foreign exchange, was down 1% year over year, primarily driven by lower Sanger Sequencing and Next Generation Sequencing revenue, partially offset by growth in Gene Synthesis.
Summary of GAAP Earnings Results - Continuing Operations
•Operating income was $2.5 million. Operating margin was 1.5%, an increase of 30 basis points year over year.
◦Gross margin was 46.0%, an increase of 60 basis points year over year, primarily driven by improved operating leverage, favorable mix and the benefits of ongoing cost initiatives. This improvement was partially offset by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio, as well as quality remediation and rework activities in Automated Stores.
◦Operating expenses in the quarter were $74 million, up 6% year over year, primarily driven by higher research and development expenses, higher selling, general and administrative expenses, as well as higher restructuring charges, partially offset by a reversal of stock-based compensation expense related to our former Chief Executive Officer’s unvested awards.
•Total other income included $5 million of net interest income, consistent with the prior year period.
•Diluted EPS from continuing operations was $0.14 compared to $1.12 in the fourth quarter of fiscal year 2025. Diluted EPS from discontinued operations was $0.02, compared to ($0.02) a year ago. Total diluted EPS was $0.16, compared to $1.11 a year ago.
Summary of Non-GAAP Earnings Results - Continuing Operations
•Adjusted operating income was $11.5 million. Adjusted operating margin was 6.9%, an increase of 120 basis points year over year.
◦Adjusted gross margin was 47.2%, an increase of 50 basis points year over year, primarily driven by improved operating leverage, favorable mix and the benefits of ongoing cost initiatives. This improvement was partially offset by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio, as well as quality remediation and rework activities in Automated Stores.
◦Adjusted operating expenses in the quarter were $67 million, up 3% year over year, mainly driven by higher research and development expenses, partially offset by a reversal of stock-based compensation expense related to our former Chief Executive Officer’s unvested awards.
•Adjusted EBITDA was $19.4 million, and Adjusted EBITDA margin was 11.6%, a decrease of 140 basis points year over year.
•Adjusted diluted EPS was $0.28, compared to $0.21 one year ago.
Full Year Fiscal 2026 Results - Continuing Operations
•Revenue was $622 million, up 5% year over year. Organic revenue, which excludes a 1-percentage point impact from foreign exchange and a 2-percentage point impact from the acquisition of UK Biocentre Limited, was up 2% year over year, reflecting higher revenue in Sample Management Solutions and Multiomics.
2
•Sample Management Solutions revenue was $344 million, up 6% year over year.
◦Organic revenue, which excludes the impact from foreign exchange and the contribution from the acquisition of UK Biocentre Limited, was up 2%, mainly driven by higher revenue in Sample Repository Services and Consumables and Instruments, partially offset by lower revenue in Automated Stores and Cryogenic Systems.
•Multiomics revenue was $277 million, up 3% year over year.
◦Organic revenue, which excludes the impact from foreign exchange, was up 1% year over year, primarily driven by higher revenue in Next Generation Sequencing and Gene Synthesis, partially offset by lower Sanger Sequencing revenue.
Summary of GAAP Earnings Results - Continuing Operations
•Operating loss was $174.7 million. Operating margin was (28.1%), compared to (4.5%) in fiscal 2025.
◦Gross margin was 44.2%, a decrease of 130 basis points year over year, primarily driven by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio as well as costs related to quality remediation and rework activities in Automated Stores, and an increase in excess and obsolete inventory reserves. These impacts were partially offset by improved operating leverage and the benefits of ongoing cost initiatives.
◦Operating expenses were $450 million, an increase of 51% year over year, primarily driven by a non-cash goodwill impairment charge of $149 million. The increase also reflects higher research and development expenses, partially offset by lower selling, general and administrative expenses, including a reversal of stock-based compensation expense related to our former Chief Executive Officer’s unvested awards.
•Total other income included $18 million of net interest income and $6 million of other income, including $4 million related to the non-cash settlement of a preexisting contractual relationship with UK Biocentre Limited, compared with $19 million and $1 million, respectively, in fiscal 2025.
•Diluted EPS from continuing operations was ($3.50) compared to $0.53 in fiscal year 2025. Diluted EPS from discontinued operations was ($0.20), compared to ($1.75) a year ago. Total diluted EPS was ($3.70), compared to ($1.22) a year ago.
Summary of Non-GAAP Earnings Results - Continuing Operations
•Adjusted operating income was $9.8 million. Adjusted operating margin was 1.6%, a decrease of 110 basis points year over year.
◦Adjusted gross margin was 45.5%, a decrease of 130 basis points year over year, primarily driven by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio as well as costs related to quality remediation and rework activities in Automated Stores, and an increase in excess and obsolete inventory reserves. These impacts were partially offset by improved operating leverage and the benefits of ongoing cost initiatives.
◦Adjusted operating expenses were $273 million, an increase of 4% year over year, driven by higher research and development expenses and higher selling, general and administrative expenses, partially offset by the reversal of stock-based compensation expense related to our former Chief Executive Officer’s unvested awards.
•Adjusted EBITDA was $58.3 million, and Adjusted EBITDA margin was 9.4%, a decrease of 180 basis points year over year.
•Adjusted diluted EPS was $0.48, compared to $0.51 one year ago.
Cash and Liquidity as of September 30, 2026
•The Company ended fiscal year 2026 with a total balance of cash, cash equivalents, restricted cash and marketable securities of $506 million.
•Operating cash flow was $22 million in the quarter. Capital expenditures were $10 million, and free cash flow (cash flow from operations less capital expenditures) was $12 million. For the full year, operating cash flow was $58 million, capital expenditures were $30 million, and free cash flow was $27 million.
3
Recent Strategic Investments
Elegen Agreements
•On October 28, 2026, the Company entered into a Technology, Equipment and License Agreement and a Master Services and Supply Agreement with Elegen Corp. (“Elegen”) to expand the Company’s gene synthesis capabilities. Under the agreements, the Company obtained an exclusive, royalty-free license to certain Elegen gene synthesis and cell-free cloning technologies, subject to certain restrictions specified in the agreements, and entered into related equipment, supply and service arrangements. The license has an initial five-year term and requires fixed license payments totaling $23.0 million. The Company has an option, exercisable between 12 and 18 months after execution, to convert the license to an irrevocable, perpetual, exclusive, royalty-free license for $25.0 million, plus any unpaid license fees, subject to the license’s terms. Aggregate capital deployment under the agreements is expected to range from approximately $32.0 million to $71.0 million, depending on future equipment purchases and whether the Company exercises the conversion option.
SynPlexity Acquisition
•On October 28, 2026, the Company acquired SynPlexity Inc. (“SynPlexity”), a synthetic biology company, for a base purchase price of $15.0 million in cash, of which approximately $2.5 million was held back, subject to customary closing and post-closing adjustments. The purchase agreement also provides for contingent consideration of up to $10.0 million based on the achievement of a specified revenue milestone through September 30, 2029. SynPlexity is a DNA assembly technology company providing products and services centered on large, multiplexed gene libraries for functional screening, drug discovery, therapeutics, and other applications. The acquisition is intended to expand the Company’s gene synthesis capabilities within its Multiomics business. Due to the timing of the acquisition, the initial accounting for the business combination is incomplete and certain acquisition-related disclosures are not yet available.
Share Repurchase Program Update
•On December 8, 2025, our Board of Directors approved a share repurchase program authorizing the repurchase of up to $250 million of our common stock through December 31, 2028, or the 2025 Repurchase Program. Repurchases under the 2025 Repurchase Program may be made in the open market or through privately negotiated transactions (including under an accelerated share repurchase agreement), or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act, subject to market and business conditions, legal requirements, and other factors. During the fiscal year ended September 30, 2026, the Company repurchased 4.4 million shares of common stock for $118.2 million (excluding fees, commissions, and excise tax) in open market repurchases pursuant to the 2025 Repurchase Program. As of September 30, 2026, $131.8 million remained available for future repurchases under the 2025 Repurchase Program.
First Quarter Fiscal 2027 Guidance
•Total organic revenue growth is expected to range approximately between 3%-4% relative to the first quarter of fiscal 2026.
•Adjusted EBITDA margin is expected to expand by approximately 100 to 150 basis points relative to the first quarter of fiscal 2026.
Full Year Fiscal 2027 Guidance
The Company expects total reported revenue from continuing operations to range approximately between $648 to $660 million for the fiscal year ending September 30, 2027.
•Total organic revenue growth is expected to range approximately between up 3% to 5% relative to fiscal 2026.
•Organic revenue for Sample Management Solutions is expected to grow mid-single-digits.
•Organic revenue for Multiomics is expected to grow low-single-digits.
•The high end of the fiscal 2027 revenue outlook includes the potential contributions from Elegen and SynPlexity. Fiscal 2027 is expected to be primarily a year of integration, scale-up, and commercialization of these capabilities.
•Adjusted EBITDA margin expansion of 200 to 250 basis points year-over-year, inclusive of the expected dilution of 100 basis points associated with the Elegen agreements and SynPlexity acquisition.
•Free cash flow (cash flow from operations less capital expenditures) is expected to improve approximately 25%, relative to fiscal 2026.
4
Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's control, or cannot be reasonably predicted. These items are uncertain and could have a significant impact on the Company’s GAAP results for the guidance periods. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures, governance-related matters, goodwill and intangible impairments, stock-based compensation, and other gains and charges that are not representative of the normal operations of the business.
Conference Call and Webcast
Azenta management will webcast its fourth quarter and full year fiscal 2026 earnings conference call on November 11, 2026 at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.
The call will be broadcast live over the Internet and, together with presentation materials and supplemental information referenced on the call, will be hosted at the Investor Relations section of Azenta’s website at https://investors.azenta.com/events. The supplemental information is being posted at the time of this earnings release, and the presentation materials will be posted ahead of the earnings call. A replay of the webcast will be archived on the website for convenient on-demand access.
Regulation G – Use of Non-GAAP Financial Measures
This release includes non-GAAP financial measures, including organic revenue, Adjusted gross profit and margin, Adjusted operating income, expenses and margin, EBITDA, Adjusted EBITDA and Adjusted EBITDA margin, Adjusted net income, Adjusted diluted EPS and free cash flow. Management believes these measures provide investors with additional insight into the results of the Company’s business operations, enhance period-to-period comparability and facilitate comparison with peers. Management uses these measures to evaluate business performance and uses organic revenue (referred to as Core Revenue in the Company’s proxy statement), Adjusted EBITDA and free cash flow in determining compensation under the Company’s annual incentive plan. These non-GAAP financial measures are not presented in accordance with, and are not substitutes for, financial measures prepared in accordance with U.S. generally accepted accounting principles, or GAAP, and should be considered together with the most directly comparable GAAP financial measures. These measures may not be comparable to similarly titled measures used by other companies.
These measures are presented on a continuing operations basis, except free cash flow, which is presented on a total company basis inclusive of B Medical Systems. Adjusted diluted EPS does not exclude stock-based compensation; the Company separately presents Adjusted net income excluding stock-based compensation. Reconciliations to the most directly comparable GAAP measures, and descriptions of the adjustments, are included at the end of this release under “Notes on Non-GAAP Financial Measures.” Certain amounts may not sum due to rounding, and all percentages are calculated using unrounded amounts.
“Safe Harbor Statement” under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended
Some statements in this release are forward-looking statements within the meaning of the federal securities laws. These statements are neither promises nor guarantees and involve risks and uncertainties, both known and unknown, that could cause Azenta’s actual financial or business results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on the facts and assumptions known to management as of the date they are made.
5
Forward-looking statements include, but are not limited to, statements regarding the Company’s fiscal 2027 guidance and outlook, including revenue, organic revenue growth, Adjusted EBITDA margin expansion and free cash flow expectations; expectations regarding the implementation, integration, commercialization and anticipated benefits of the Company’s strategic investments, including the Elegen agreements and SynPlexity acquisition; potential future capital deployment under the Elegen agreements, including future equipment purchases and the potential exercise of the license conversion option; expectations regarding the timing, execution and benefits of operational, commercial and organizational transformation initiatives; anticipated productivity improvements, cost actions and margin expansion; expectations regarding demand trends and end-market conditions; and the Company’s long-range financial objectives. Factors that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to: the Company’s ability to achieve its fiscal 2027 outlook; the Company’s ability to successfully implement, integrate and commercialize its strategic investments, including the Elegen agreements and SynPlexity acquisition, and realize their anticipated benefits; risks associated with future capital deployment and other obligations under the Elegen agreements; the ability to achieve anticipated revenue, margin, cost and productivity improvements; changes in customer demand, purchasing behavior or funding conditions in the markets the Company serves; macroeconomic, geopolitical or regulatory developments; foreign currency fluctuations; supply chain disruptions; competitive dynamics; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
Azenta expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.
AZENTA INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis and Investor Relations
ir@azenta.com
Maria Isabel Cuartas
Manager Investor Relations
ir@azenta.com
6
AZENTA, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(In thousands, except per share data)
| Three Months Ended September 30, | Year Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Products | $ | 45,306 | $ | 48,020 | $ | 165,291 | $ | 173,189 | |||||||||||||||
| Services | 121,782 | 111,172 | 456,412 | 420,632 | |||||||||||||||||||
| Total revenue | 167,088 | 159,192 | 621,703 | 593,821 | |||||||||||||||||||
| Cost of revenue | |||||||||||||||||||||||
| Products | 23,961 | 26,287 | 95,850 | 94,894 | |||||||||||||||||||
| Services | 66,260 | 60,631 | 250,889 | 228,647 | |||||||||||||||||||
| Total cost of revenue | 90,221 | 86,918 | 346,739 | 323,541 | |||||||||||||||||||
| Gross profit | 76,867 | 72,274 | 274,964 | 270,280 | |||||||||||||||||||
| Operating expenses | |||||||||||||||||||||||
| Research and development | 10,443 | 8,258 | 37,918 | 30,390 | |||||||||||||||||||
| Selling, general and administrative | 61,860 | 61,709 | 257,526 | 261,563 | |||||||||||||||||||
| Impairment of goodwill and intangible assets | — | — | 149,083 | — | |||||||||||||||||||
| Restructuring charges | 2,058 | 406 | 5,136 | 5,171 | |||||||||||||||||||
| Total operating expenses | 74,361 | 70,373 | 449,663 | 297,124 | |||||||||||||||||||
| Operating income (loss) | 2,506 | 1,901 | (174,699) | (26,844) | |||||||||||||||||||
| Other income (expense) | |||||||||||||||||||||||
| Interest income, net | 4,520 | 5,019 | 17,830 | 18,779 | |||||||||||||||||||
| Other income (expense), net | 526 | (620) | 5,863 | 922 | |||||||||||||||||||
| Income (loss) from continuing operations before income taxes | 7,552 | 6,300 | (151,006) | (7,143) | |||||||||||||||||||
| Income tax expense (benefit) | 1,678 | (45,353) | 6,860 | (31,601) | |||||||||||||||||||
| Income (loss) from continuing operations | 5,874 | 51,653 | (157,866) | 24,458 | |||||||||||||||||||
| Income (loss) from discontinued operations, net of tax | 915 | (776) | (9,119) | (80,221) | |||||||||||||||||||
| Net income (loss) | $ | 6,789 | $ | 50,877 | $ | (166,985) | $ | (55,763) | |||||||||||||||
| Basic net income (loss) per share: | |||||||||||||||||||||||
| Income (loss) from continuing operations | $ | 0.14 | $ | 1.13 | $ | (3.50) | $ | 0.53 | |||||||||||||||
| Income (loss) from discontinued operations, net of tax | $ | 0.02 | $ | (0.02) | $ | (0.20) | $ | (1.75) | |||||||||||||||
| Net income (loss) per share | $ | 0.16 | $ | 1.11 | $ | (3.70) | $ | (1.22) | |||||||||||||||
| Diluted net income (loss) per share: | |||||||||||||||||||||||
| Income (loss) from continuing operations | $ | 0.14 | $ | 1.12 | $ | (3.50) | $ | 0.53 | |||||||||||||||
| Income (loss) from discontinued operations, net of tax | $ | 0.02 | $ | (0.02) | $ | (0.20) | $ | (1.75) | |||||||||||||||
| Diluted net income (loss) per share | $ | 0.16 | $ | 1.11 | $ | (3.70) | $ | (1.22) | |||||||||||||||
| Weighted average shares used in computing net income (loss) per share: | |||||||||||||||||||||||
| Basic | 43,264 | 45,833 | 45,130 | 45,743 | |||||||||||||||||||
| Diluted | 43,465 | 45,994 | 45,130 | 45,896 | |||||||||||||||||||
7
AZENTA, INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands, except share and per share data)
| September 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| Assets | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | 193,798 | $ | 279,783 | |||||||
| Short-term marketable securities | 138,886 | 61,137 | |||||||||
Accounts receivable, net of allowance for expected credit losses ($4,111 and $4,649, respectively) | 143,418 | 142,181 | |||||||||
| Inventories | 77,122 | 74,956 | |||||||||
| Short-term restricted cash | 265 | 2,359 | |||||||||
| Refundable income taxes | 10,717 | 9,728 | |||||||||
| Contract assets | 32,971 | 37,295 | |||||||||
| Prepaid expenses and other current assets | 26,359 | 27,365 | |||||||||
| Current assets held for sale | — | 73,535 | |||||||||
| Total current assets | 623,536 | 708,339 | |||||||||
| Property, plant and equipment, net | 175,245 | 153,954 | |||||||||
| Long-term marketable securities | 169,200 | 201,585 | |||||||||
| Long-term deferred tax assets | 499 | 726 | |||||||||
| Operating lease right-of-use assets | 59,012 | 54,048 | |||||||||
| Goodwill | 546,259 | 702,395 | |||||||||
| Intangible assets, net | 79,998 | 101,814 | |||||||||
| Long term income taxes receivable | 45,600 | 45,600 | |||||||||
| Other assets | 9,034 | 6,115 | |||||||||
| Noncurrent assets held for sale | — | 85,006 | |||||||||
| Total assets | $ | 1,708,383 | $ | 2,059,582 | |||||||
| Liabilities and stockholders' equity | |||||||||||
| Current liabilities | |||||||||||
| Accounts payable | $ | 55,219 | $ | 37,722 | |||||||
| Deferred revenue | 40,081 | 31,569 | |||||||||
| Derivative liability | 25,641 | 33,420 | |||||||||
| Accrued warranty and retrofit costs | 3,544 | 4,713 | |||||||||
| Accrued compensation and benefits | 33,396 | 35,799 | |||||||||
| Customer deposits | 33,566 | 26,499 | |||||||||
| Accrued income taxes payable | 3,517 | 9,416 | |||||||||
| Accrued expenses and other current liabilities | 38,123 | 30,268 | |||||||||
| Current liabilities held for sale | — | 28,268 | |||||||||
| Total current liabilities | 233,087 | 237,674 | |||||||||
| Long-term deferred tax liabilities | 15,338 | 18,245 | |||||||||
| Long-term operating lease liabilities | 51,874 | 51,244 | |||||||||
| Other long-term liabilities | 10,863 | 11,142 | |||||||||
| Noncurrent liabilities held for sale | — | 14,291 | |||||||||
| Total liabilities | $ | 311,162 | $ | 332,596 | |||||||
| Stockholders' equity | |||||||||||
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding | — | — | |||||||||
Common stock, $0.01 par value - 125,000,000 shares authorized, 55,284,062 shares issued and 41,757,019 shares outstanding at September 30, 2026, 59,320,848 shares issued and 45,858,979 shares outstanding at September 30, 2025 | 553 | 594 | |||||||||
| Additional paid-in capital | 424,268 | 529,605 | |||||||||
| Accumulated other comprehensive loss | (77,398) | (22,213) | |||||||||
Treasury stock, at cost - 13,527,043 shares at September 30, 2026 and 13,461,869 shares at September 30, 2025 | (203,173) | (200,956) | |||||||||
| Retained earnings | 1,252,971 | 1,419,956 | |||||||||
| Total stockholders' equity | 1,397,221 | 1,726,986 | |||||||||
| Total liabilities and stockholders' equity | $ | 1,708,383 | $ | 2,059,582 | |||||||
8
AZENTA, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)
| Year Ended September 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| Cash flows from operating activities | |||||||||||
| Net loss | $ | (166,985) | $ | (55,763) | |||||||
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 56,520 | 61,209 | |||||||||
| Impairment of goodwill and intangible assets | 149,083 | — | |||||||||
| Non-cash gain from settlement of preexisting contractual relationship | (3,716) | — | |||||||||
| Loss on assets held for sale | 9,491 | 93,118 | |||||||||
| Property, plant and equipment and other asset write-offs | 1,363 | 3,478 | |||||||||
| Inventory write-downs | 4,015 | — | |||||||||
| Other non-cash adjustments | (1,985) | — | |||||||||
| Stock-based compensation | 12,243 | 20,881 | |||||||||
| Amortization and accretion on marketable securities | (1,424) | (1,578) | |||||||||
| Deferred income taxes | (5,170) | (27,038) | |||||||||
| Loss on disposals of property, plant and equipment | 14 | 711 | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable | 4,423 | 21,039 | |||||||||
| Inventories | (8,041) | (2,671) | |||||||||
| Accounts payable | 12,662 | 1,037 | |||||||||
| Deferred revenue | 6,020 | 641 | |||||||||
| Accrued warranty and retrofit costs | (424) | (435) | |||||||||
| Accrued compensation and tax withholdings | (1,418) | 7,427 | |||||||||
| Long term income taxes receivable | — | (45,600) | |||||||||
| Other assets and liabilities | (9,165) | (4,275) | |||||||||
| Net cash provided by operating activities | 57,506 | 72,181 | |||||||||
| Cash flows from investing activities | |||||||||||
| Purchases of property, plant and equipment | (30,079) | (33,857) | |||||||||
| Purchases of marketable securities and other investments | (375,684) | (451,409) | |||||||||
| Sales and maturities of marketable securities | 328,609 | 389,452 | |||||||||
| Acquisition of UK Biocentre, net of cash acquired | (11,150) | — | |||||||||
| Proceeds from other investment | — | 2,130 | |||||||||
| Net investment hedge settlement | — | 3,223 | |||||||||
| Proceeds from the sale of B Medical Systems business, net of cash transferred | 54,503 | — | |||||||||
| Net cash used in investing activities | (33,801) | (90,461) | |||||||||
| Cash flows from financing activities | |||||||||||
| Proceeds from issuance of common stock | 2,204 | 2,770 | |||||||||
| Payments of finance leases | (748) | (985) | |||||||||
| Withholding tax payments on net share settlements on equity awards | (2,669) | — | |||||||||
| Share repurchases | (118,286) | — | |||||||||
| Excise tax payment for settled share repurchases | — | (11,376) | |||||||||
| Net cash used in financing activities | (119,499) | (9,591) | |||||||||
| Effects of exchange rate changes on cash, cash equivalents and restricted cash | (2,576) | 3,566 | |||||||||
| Net decrease in cash, cash equivalents and restricted cash | (98,370) | (24,305) | |||||||||
| Cash, cash equivalents and restricted cash, beginning of period | 296,685 | 320,990 | |||||||||
| Cash, cash equivalents and restricted cash, end of period | $ | 198,315 | $ | 296,685 | |||||||
| Supplemental disclosures: | |||||||||||
| Cash paid for income taxes, net | $ | 18,118 | $ | 6,568 | |||||||
| Purchases of property, plant and equipment included in accounts payable and accrued expenses | $ | 9,404 | $ | 5,546 | |||||||
| Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets | |||||||||||
| Year Ended September 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| Cash and cash equivalents of continuing operations | $ | 193,798 | $ | 279,783 | |||||||
| Cash included in current assets held for sale | — | 13,206 | |||||||||
| Short-term restricted cash | 265 | 2,359 | |||||||||
| Long-term restricted cash included in other assets | 4,252 | 1,337 | |||||||||
| Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows | $ | 198,315 | $ | 296,685 | |||||||
9
Notes on Non-GAAP Financial Measures - Continuing Operations
Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, costs related to the Company’s business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.
| Quarter Ended | |||||||||||||||||||||||||||||||||||
| September 30, 2026 | June 30, 2026 | September 30, 2025 | |||||||||||||||||||||||||||||||||
| Amounts in thousands, except per share data | $ | per diluted share | $ | per diluted share | $ | per diluted share | |||||||||||||||||||||||||||||
| Net income (loss) from continuing operations | $ | 5,874 | $ | 0.14 | $ | (1,529) | $ | (0.03) | $ | 51,653 | $ | 1.12 | |||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||
| Amortization of completed technology | 2,076 | 0.05 | 2,082 | 0.05 | 2,088 | 0.05 | |||||||||||||||||||||||||||||
| Amortization of other intangible assets | 3,606 | 0.08 | 3,616 | 0.08 | 3,977 | 0.09 | |||||||||||||||||||||||||||||
Transformation costs(1) | 804 | 0.02 | 272 | 0.01 | 634 | 0.01 | |||||||||||||||||||||||||||||
| Restructuring charges | 2,058 | 0.05 | 513 | 0.01 | 406 | 0.01 | |||||||||||||||||||||||||||||
Merger and acquisition costs(3) | 363 | 0.01 | 2,248 | 0.05 | 87 | 0.00 | |||||||||||||||||||||||||||||
Non-recurring other adjustments(4) | 142 | 0.00 | — | — | — | — | |||||||||||||||||||||||||||||
| Purchase accounting adjustments | 117 | 0.00 | 154 | 0.00 | — | — | |||||||||||||||||||||||||||||
Tax adjustments(5) | — | — | — | — | (46,960) | (1.02) | |||||||||||||||||||||||||||||
| Tax effect of adjustments | (2,753) | (0.06) | (198) | 0.00 | (2,246) | (0.05) | |||||||||||||||||||||||||||||
| Adjusted net income from continuing operations | $ | 12,287 | $ | 0.28 | $ | 7,158 | $ | 0.16 | $ | 9,639 | $ | 0.21 | |||||||||||||||||||||||
| Stock-based compensation, pre-tax | (2,412) | (0.06) | 4,692 | 0.10 | 3,901 | 0.08 | |||||||||||||||||||||||||||||
| Tax rate | 19 | % | — | 13 | % | — | 17 | % | — | ||||||||||||||||||||||||||
| Stock-based compensation, net of tax | (1,954) | (0.04) | 4,082 | 0.09 | 3,238 | 0.07 | |||||||||||||||||||||||||||||
| Adjusted net income excluding stock-based compensation - continuing operations | $ | 10,333 | $ | 0.24 | $ | 11,240 | $ | 0.25 | $ | 12,877 | $ | 0.28 | |||||||||||||||||||||||
| Shares used in computing adjusted diluted net income per share | 43,465 | 45,286 | 45,994 | ||||||||||||||||||||||||||||||||
10
| Year Ended | |||||||||||||||||||||||
| September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||
| Amounts in thousands, except per share data | $ | per diluted share | $ | per diluted share | |||||||||||||||||||
| Net income (loss) from continuing operations | $ | (157,866) | $ | (3.50) | $ | 24,458 | $ | 0.53 | |||||||||||||||
| Adjustments: | |||||||||||||||||||||||
| Amortization of completed technology | 8,093 | 0.18 | 7,965 | 0.17 | |||||||||||||||||||
| Amortization of other intangible assets | 14,336 | 0.32 | 16,475 | 0.36 | |||||||||||||||||||
Transformation costs(1) | 2,717 | 0.06 | 10,405 | 0.23 | |||||||||||||||||||
| Restructuring charges | 5,136 | 0.11 | 5,171 | 0.11 | |||||||||||||||||||
Impairment of goodwill and intangible assets(2) | 149,083 | 3.30 | — | — | |||||||||||||||||||
Merger and acquisition costs(3) | 4,799 | 0.11 | 2,403 | 0.05 | |||||||||||||||||||
Non-recurring other adjustments(4) | (3,716) | (0.08) | (2,130) | (0.05) | |||||||||||||||||||
| Purchase accounting adjustment | 271 | 0.01 | — | — | |||||||||||||||||||
Tax adjustments(5) | — | — | (39,660) | (0.86) | |||||||||||||||||||
| Tax effect of adjustments | (1,048) | (0.02) | (1,675) | (0.04) | |||||||||||||||||||
| Other adjustments | — | — | 38 | 0.00 | |||||||||||||||||||
| Adjusted net income from continuing operations | $ | 21,805 | $ | 0.48 | $ | 23,450 | $ | 0.51 | |||||||||||||||
| Stock-based compensation, pre-tax | 12,410 | 0.27 | 19,849 | 0.43 | |||||||||||||||||||
| Tax rate | 19% | — | 17 | % | — | ||||||||||||||||||
| Stock-based compensation, net of tax | 10,052 | 0.22 | 16,475 | 0.36 | |||||||||||||||||||
| Adjusted net income excluding stock-based compensation - continuing operations | $ | 31,857 | $ | 0.71 | $ | 39,925 | $ | 0.87 | |||||||||||||||
| Shares used in computing adjusted diluted net income per share | 45,130 | 45,896 | |||||||||||||||||||||
(1)Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.
(2)Represents a non-cash goodwill impairment charge recognized in the second quarter of fiscal 2026 as a result of the Company's quantitative goodwill impairment analysis as of March 31, 2026, including $112.4 million for the Multiomics reporting unit and $36.6 million for the Sample Management Solutions reporting unit.
(3)Merger and acquisition costs consist primarily of legal, accounting, valuation, and strategic advisory fees incurred in connection with acquisition and integration activities.
(4)The Company recognized $3.9 million non-cash gain from the settlement of the pre-existing contractual relationship with UK Biocentre Limited in the second quarter of fiscal 2026. The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis in the second quarter of fiscal 2025. These are non-recurring and non-operational adjustments.
(5)The tax adjustments for the fourth quarter of fiscal year 2025 and full year includes a one-time $45.6 million benefit related to a worthless stock deduction on one of the Company's foreign subsidiaries that is excluded from non-GAAP results. The full year adjustments also includes a one-time tax expense of $6.4 million driven by a repatriation of historical earnings from China.
11
| Quarter Ended | Year Ended | ||||||||||||||||||||||||||||
| Dollars in thousands | September 30, 2026 | June 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||
| GAAP net income (loss) | $ | 6,789 | $ | 2,456 | $ | 50,877 | $ | (166,985) | $ | (55,763) | |||||||||||||||||||
| Less: Income (loss) from discontinued operations | 915 | 3,985 | (776) | (9,119) | (80,221) | ||||||||||||||||||||||||
| GAAP net income (loss) from continuing operations | 5,874 | (1,529) | 51,653 | (157,866) | 24,458 | ||||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||
| Interest income, net | (4,520) | (3,825) | (5,019) | (17,830) | (18,779) | ||||||||||||||||||||||||
| Income tax expense (benefit) | 1,678 | 2,375 | (45,353) | 6,860 | (31,601) | ||||||||||||||||||||||||
| Depreciation | 9,579 | 7,861 | 8,338 | 33,986 | 32,033 | ||||||||||||||||||||||||
| Amortization of completed technology | 2,076 | 2,082 | 2,088 | 8,093 | 7,965 | ||||||||||||||||||||||||
| Amortization of other intangible assets | 3,606 | 3,616 | 3,977 | 14,336 | 16,475 | ||||||||||||||||||||||||
| Earnings before interest, taxes, depreciation and amortization - Continuing operations | $ | 18,293 | $ | 10,580 | $ | 15,684 | $ | (112,421) | $ | 30,551 | |||||||||||||||||||
| Quarter Ended | Year Ended | ||||||||||||||||||||||||||||
| Dollars in thousands | September 30, 2026 | June 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||
| Earnings before interest, taxes, depreciation and amortization - Continuing operations | $ | 18,293 | $ | 10,580 | $ | 15,684 | $ | (112,421) | $ | 30,551 | |||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||
| Stock-based compensation | (2,412) | 4,692 | 3,901 | 12,410 | 19,849 | ||||||||||||||||||||||||
| Restructuring charges | 2,058 | 513 | 406 | 5,136 | 5,171 | ||||||||||||||||||||||||
Impairment of goodwill and intangible assets(1) | — | — | — | 149,083 | — | ||||||||||||||||||||||||
Merger and acquisition costs(2) | 363 | 2,248 | 87 | 4,799 | 2,403 | ||||||||||||||||||||||||
Transformation costs(3) | 804 | 272 | 634 | 2,717 | 10,405 | ||||||||||||||||||||||||
Non-recurring other adjustments(4) | 142 | — | — | (3,716) | (2,130) | ||||||||||||||||||||||||
| Purchase accounting adjustment | 117 | 154 | — | 271 | — | ||||||||||||||||||||||||
| Other adjustments | — | — | — | 16 | 34 | ||||||||||||||||||||||||
| Adjusted earnings before interest, taxes, depreciation and amortization - Continuing operations | $ | 19,365 | $ | 18,459 | $ | 20,712 | $ | 58,295 | $ | 66,283 | |||||||||||||||||||
(1)Represents a non-cash goodwill impairment charge recognized in the second quarter of fiscal 2026 as a result of the Company's quantitative goodwill impairment analysis as of March 31, 2026, including $112.4 million for the Multiomics reporting unit and $36.6 million for the Sample Management Solutions reporting unit.
(2)Merger and acquisition costs consist primarily of legal, accounting, valuation, and strategic advisory fees incurred in connection with acquisition and integration activities.
(3)Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.
(4)The Company recognized $3.9 million non-cash gain from the settlement of the pre-existing contractual relationship with UK Biocentre Limited in the second quarter of fiscal 2026. The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis in the second quarter of fiscal 2025. These are non-recurring and non-operational adjustments.
12
| Quarter Ended | |||||||||||||||||||||||||||||||||||
| Dollars in thousands | September 30, 2026 | June 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||||||||||
| GAAP gross profit | $ | 76,867 | 46.0 | % | $ | 72,356 | 44.9 | % | $ | 72,274 | 45.4 | % | |||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||
| Amortization of completed technology | 2,076 | 1.2 | % | 2,082 | 1.3 | % | 2,088 | 1.3 | % | ||||||||||||||||||||||||||
| Adjusted gross profit | $ | 78,943 | 47.2 | % | $ | 74,438 | 46.2 | % | $ | 74,362 | 46.7 | % | |||||||||||||||||||||||
| Year Ended | ||||||||||||||||||||||||||
| Dollars in thousands | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||
| GAAP gross profit | $ | 274,964 | 44.2 | % | $ | 270,280 | 45.5 | % | ||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||
| Amortization of completed technology | 8,093 | 1.3 | % | 7,965 | 1.3 | % | ||||||||||||||||||||
Transformation costs(1) | — | — | % | 52 | 0.0 | % | ||||||||||||||||||||
| Other Adjustments | — | — | % | 18 | 0.0 | % | ||||||||||||||||||||
| Adjusted gross profit | $ | 283,057 | 45.5 | % | $ | 278,315 | 46.9 | % | ||||||||||||||||||
(1)Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.
| Sample Management Solutions | Multiomics | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Quarter Ended | Quarter Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dollars in thousands | September 30, 2026 | June 30, 2026 | September 30, 2025 | September 30, 2026 | June 30, 2026 | September 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| GAAP gross profit | $ | 44,408 | 47.4 | % | $ | 39,126 | 44.3 | % | $ | 41,175 | 47.9 | % | $ | 32,459 | 44.2 | % | $ | 33,230 | 45.6 | % | $ | 31,094 | 42.5 | % | |||||||||||||||||||||||||||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Amortization of completed technology | 1,386 | 1.5 | % | 1,393 | 1.6 | % | 1,226 | 1.4 | % | 690 | 0.9 | % | 689 | 0.9 | % | 862 | 1.2 | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Adjusted gross profit | $ | 45,794 | 48.9 | % | $ | 40,519 | 45.9 | % | $ | 42,401 | 49.3 | % | $ | 33,149 | 45.1 | % | $ | 33,919 | 46.5 | % | $ | 31,956 | 43.7 | % | |||||||||||||||||||||||||||||||||||||||||||||||
| Segment Total | |||||||||||||||||||||||||||||||||||
| Quarter Ended | |||||||||||||||||||||||||||||||||||
| Dollars in thousands | September 30, 2026 | June 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||||||||||
| GAAP gross profit | $ | 76,867 | 46.0 | % | $ | 72,356 | 44.9 | % | $ | 72,274 | 45.4 | % | |||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||
| Amortization of completed technology | 2,076 | 1.2 | % | 2,082 | 1.3 | % | 2,088 | 1.3 | % | ||||||||||||||||||||||||||
| Adjusted gross profit | $ | 78,943 | 47.2 | % | $ | 74,438 | 46.2 | % | $ | 74,362 | 46.7 | % | |||||||||||||||||||||||
| Sample Management Solutions | Multiomics | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Year Ended | Year Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dollars in thousands | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||
| GAAP gross profit | $ | 156,401 | 45.4 | % | $ | 156,645 | 48.3 | % | $ | 118,563 | 42.8 | % | $ | 113,635 | 42.2 | % | |||||||||||||||||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Amortization of completed technology | 5,344 | 1.6 | % | 4,522 | 1.4 | % | 2,749 | 1.0 | % | 3,443 | 1.3 | % | |||||||||||||||||||||||||||||||||||||||||
Transformation costs(1) | — | — | % | 52 | 0.0 | % | — | — | % | — | — | % | |||||||||||||||||||||||||||||||||||||||||
| Other Adjustments | — | — | % | 26 | 0.0 | % | — | — | % | (8) | 0.0 | % | |||||||||||||||||||||||||||||||||||||||||
| Adjusted gross profit | $ | 161,745 | 47.0 | % | $ | 161,245 | 49.7 | % | $ | 121,312 | 43.8 | % | $ | 117,070 | 43.5 | % | |||||||||||||||||||||||||||||||||||||
13
| Segment Total | ||||||||||||||||||||||||||
| Year Ended | ||||||||||||||||||||||||||
| Dollars in thousands | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||
| GAAP gross profit | $ | 274,964 | 44.2 | % | $ | 270,280 | 45.5 | % | ||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||
| Amortization of completed technology | 8,093 | 1.3 | % | 7,965 | 1.3 | % | ||||||||||||||||||||
Transformation costs(1) | — | — | % | 52 | 0.0 | % | ||||||||||||||||||||
| Other Adjustments | — | — | % | 18 | 0.0 | % | ||||||||||||||||||||
| Adjusted gross profit | $ | 283,057 | 45.5 | % | $ | 278,315 | 46.9 | % | ||||||||||||||||||
(1)Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.
| Total Segments | Corporate | Total | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Quarter Ended | Quarter Ended | Quarter Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Dollars in thousands | September 30, 2026 | June 30, 2026 | September 30, 2025 | September 30, 2026 | June 30, 2026 | September 30, 2025 | September 30, 2026 | June 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||
| GAAP operating income (loss) | $ | 9,063 | $ | 2,051 | $ | 6,986 | $ | (6,557) | $ | (6,229) | $ | (5,085) | $ | 2,506 | $ | (4,178) | $ | 1,901 | |||||||||||||||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Amortization of completed technology | 2,076 | 2,082 | 2,088 | — | — | — | 2,076 | 2,082 | 2,088 | ||||||||||||||||||||||||||||||||||||||||||||
| Amortization of other intangible assets | — | 49 | — | 3,606 | 3,567 | 3,977 | 3,606 | 3,616 | 3,977 | ||||||||||||||||||||||||||||||||||||||||||||
Transformation costs(1) | 179 | 56 | (57) | 625 | 216 | 691 | 804 | 272 | 634 | ||||||||||||||||||||||||||||||||||||||||||||
| Restructuring charges | — | — | — | 2,058 | 513 | 406 | 2,058 | 513 | 406 | ||||||||||||||||||||||||||||||||||||||||||||
Merger and acquisition costs(3) | 60 | 204 | — | 303 | 2,044 | 87 | 363 | 2,248 | 87 | ||||||||||||||||||||||||||||||||||||||||||||
| Purchase accounting and other adjustments | 154 | 154 | 73 | (38) | — | (73) | 116 | 154 | — | ||||||||||||||||||||||||||||||||||||||||||||
| Adjusted operating income (loss) | $ | 11,532 | $ | 4,596 | $ | 9,090 | $ | (3) | $ | 111 | $ | 3 | $ | 11,529 | $ | 4,707 | $ | 9,093 | |||||||||||||||||||||||||||||||||||
| Total Segments | Corporate | Total | |||||||||||||||||||||||||||||||||
| Year Ended | Year Ended | Year Ended | |||||||||||||||||||||||||||||||||
| Dollars in thousands | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | |||||||||||||||||||||||||||||
| GAAP operating income (loss) | $ | 705 | $ | 4,710 | $ | (175,404) | $ | (31,554) | $ | (174,699) | $ | (26,844) | |||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||
| Amortization of completed technology | 8,093 | 7,965 | — | — | 8,093 | 7,965 | |||||||||||||||||||||||||||||
| Amortization of other intangible assets | 86 | — | 14,250 | 16,475 | 14,336 | 16,475 | |||||||||||||||||||||||||||||
Transformation costs(1) | 348 | 2,820 | 2,369 | 7,585 | 2,717 | 10,405 | |||||||||||||||||||||||||||||
| Restructuring charges | — | — | 5,136 | 5,171 | 5,136 | 5,171 | |||||||||||||||||||||||||||||
Impairment of goodwill and intangible assets(2) | — | — | 149,083 | — | 149,083 | — | |||||||||||||||||||||||||||||
Merger and acquisition costs(3) | 264 | — | 4,535 | 2,403 | 4,799 | 2,403 | |||||||||||||||||||||||||||||
| Purchase accounting and other adjustments | 294 | 118 | — | (84) | 294 | 34 | |||||||||||||||||||||||||||||
| Adjusted operating income (loss) | $ | 9,790 | $ | 15,613 | $ | (31) | $ | (4) | $ | 9,759 | $ | 15,609 | |||||||||||||||||||||||
(1)Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.
(2)Represents non-cash goodwill impairment charges recognized in the second quarter of fiscal 2026 as a result of the Company’s quantitative goodwill impairment analysis as of March 31, 2026, including $112.4 million for the Multiomics reporting unit and $36.6 million for the Sample Management Solutions reporting unit.
(3)Merger and acquisition costs consist primarily of legal, accounting, valuation, and strategic advisory fees incurred in connection with acquisition and integration activities.
14
| Sample Management Solutions | Multiomics | Azenta Total | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Quarter Ended | Quarter Ended | Quarter Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Dollars in millions | September 30, 2026 | September 30, 2025 | Change | September 30, 2026 | September 30, 2025 | Change | September 30, 2026 | September 30, 2025 | Change | ||||||||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 94 | $ | 86 | 9 | % | $ | 73 | $ | 73 | 0 | % | $ | 167 | $ | 159 | 5 | % | |||||||||||||||||||||||||||||||||||
| Acquisitions | (4) | — | (5) | % | — | — | — | % | (4) | — | (3) | % | |||||||||||||||||||||||||||||||||||||||||
| Currency exchange rates | 0 | — | 0 | % | (1) | — | (1) | % | (0) | — | 0 | % | |||||||||||||||||||||||||||||||||||||||||
| Organic revenue | $ | 90 | $ | 86 | 4 | % | $ | 73 | $ | 73 | (1) | % | $ | 162 | $ | 159 | 2 | % | |||||||||||||||||||||||||||||||||||
| Sample Management Solutions | Multiomics | Azenta Total | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Year Ended | Year Ended | Year Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Dollars in millions | September 30, 2026 | September 30, 2025 | Change | September 30, 2026 | September 30, 2025 | Change | September 30, 2026 | September 30, 2025 | Change | ||||||||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 344 | $ | 325 | 6 | % | $ | 277 | $ | 269 | 3 | % | $ | 622 | $ | 594 | 5 | % | |||||||||||||||||||||||||||||||||||
| Acquisitions | (10) | — | (3) | % | — | — | — | % | (10) | — | (2) | % | |||||||||||||||||||||||||||||||||||||||||
| Currency exchange rates | (4) | — | (1) | % | (5) | — | (2) | % | (8) | — | (1) | % | |||||||||||||||||||||||||||||||||||||||||
| Organic revenue | $ | 331 | $ | 325 | 2 | % | $ | 273 | $ | 269 | 1 | % | $ | 604 | $ | 594 | 2 | % | |||||||||||||||||||||||||||||||||||
15